- Home
- BCDA vs NXTC Comparison
BCDA vs NXTC Comparison
Compare BCDA & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- NXTC
- Stock Information
- Founded
- BCDA N/A
- NXTC 2015
- Country
- BCDA United States
- NXTC United States
- Employees
- BCDA N/A
- NXTC N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- NXTC Health Care
- Exchange
- BCDA Nasdaq
- NXTC Nasdaq
- Market Cap
- BCDA 11.3M
- NXTC 13.0M
- IPO Year
- BCDA N/A
- NXTC 2019
- Fundamental
- Price
- BCDA $1.56
- NXTC $5.73
- Analyst Decision
- BCDA Strong Buy
- NXTC Strong Buy
- Analyst Count
- BCDA 1
- NXTC 2
- Target Price
- BCDA $25.00
- NXTC $25.50
- AVG Volume (30 Days)
- BCDA 46.4K
- NXTC 14.1K
- Earning Date
- BCDA 11-12-2025
- NXTC 11-06-2025
- Dividend Yield
- BCDA N/A
- NXTC N/A
- EPS Growth
- BCDA N/A
- NXTC N/A
- EPS
- BCDA N/A
- NXTC N/A
- Revenue
- BCDA N/A
- NXTC N/A
- Revenue This Year
- BCDA N/A
- NXTC N/A
- Revenue Next Year
- BCDA N/A
- NXTC N/A
- P/E Ratio
- BCDA N/A
- NXTC N/A
- Revenue Growth
- BCDA N/A
- NXTC N/A
- 52 Week Low
- BCDA $1.63
- NXTC $2.69
- 52 Week High
- BCDA $3.25
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- BCDA 30.27
- NXTC 66.36
- Support Level
- BCDA $2.11
- NXTC $5.19
- Resistance Level
- BCDA $2.29
- NXTC $5.90
- Average True Range (ATR)
- BCDA 0.12
- NXTC 0.28
- MACD
- BCDA -0.03
- NXTC 0.08
- Stochastic Oscillator
- BCDA 0.96
- NXTC 87.53
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.